BioCryst Pharmaceuticals, Inc. (BCRX)

NASDAQ: BCRX · IEX Real-Time Price · USD

7.14

+0.09 (1.28%)

At close: Jul 19, 2024, 4:00 PM

7.06

-0.08 (-1.12%)

Pre-market: Jul 20, 2024, 9:29 AM EDT

BioCryst Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 1994
Revenue	355.4	331.41	270.83	157.17	17.81	48.84	Upgrade
Revenue Growth (YoY)	22.68%	22.37%	72.31%	782.38%	-63.53%	136.45%	Upgrade
Cost of Revenue	5.12	4.66	6.59	7.26	1.68	4.1	Upgrade
Gross Profit	350.28	326.75	264.23	149.91	16.14	44.73	Upgrade
Selling, General & Admin	225.39	213.89	159.37	118.82	67.93	37.12	Upgrade
Research & Development	214.67	216.57	253.3	208.81	122.96	107.07	Upgrade
Operating Expenses	440.06	430.46	412.67	327.63	190.89	144.19	Upgrade
Operating Income	-89.78	-103.71	-148.44	-177.72	-174.76	-99.46	Upgrade
Interest Expense / Income	105.35	108.24	99.09	59.29	14.5	11.89	Upgrade
Other Expense / Income	13.45	14.28	-3.14	-55.21	-6.44	-2.45	Upgrade
Pretax Income	-208.58	-226.23	-244.38	-181.81	-182.81	-108.9	Upgrade
Income Tax	0	0.31	2.73	2.25	0	0	Upgrade
Net Income	-208.59	-226.54	-247.12	-184.06	-182.81	-108.9	Upgrade
Shares Outstanding (Basic)	206	192	186	179	167	116	Upgrade
Shares Outstanding (Diluted)	206	192	186	179	167	116	Upgrade
Shares Change	9.31%	3.38%	3.79%	7.08%	44.69%	12.03%	Upgrade
EPS (Basic)	-1.07	-1.18	-1.33	-1.03	-1.09	-0.94	Upgrade
EPS (Diluted)	-1.07	-1.18	-1.33	-1.03	-1.09	-0.94	Upgrade
Free Cash Flow	-103.56	-97.31	-163.2	-144.54	-135.62	-89.93	Upgrade
Free Cash Flow Per Share	-0.50	-0.51	-0.88	-0.81	-0.81	-0.78	Upgrade
Gross Margin	98.56%	98.59%	97.57%	95.38%	90.59%	91.60%	Upgrade
Operating Margin	-25.26%	-31.29%	-54.81%	-113.08%	-981.12%	-203.66%	Upgrade
Profit Margin	-58.69%	-68.36%	-91.24%	-117.11%	-1026.35%	-222.99%	Upgrade
Free Cash Flow Margin	-29.14%	-29.36%	-60.26%	-91.97%	-761.41%	-184.14%	Upgrade
EBITDA	-101.68	-116.34	-143.85	-121.74	-167.57	-96.28	Upgrade
EBITDA Margin	-28.61%	-35.10%	-53.12%	-77.46%	-940.74%	-197.16%	Upgrade
Depreciation & Amortization	1.56	1.66	1.44	0.78	0.75	0.72	Upgrade
EBIT	-103.23	-117.99	-145.29	-122.52	-168.31	-97.01	Upgrade
EBIT Margin	-29.05%	-35.60%	-53.65%	-77.95%	-944.94%	-198.64%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).